Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466906 | 0.81 | SLC6A2 (0.72) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4472110 | 0.81 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL5246721 | 0.80 | SLC6A2 (1.00) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4473789 | 0.79 | SLC6A2 (0.65) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4460437 | 0.79 | SLC6A2 (0.61) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4462991 | 0.77 | SLC6A2 (0.62) | SLC6A2SLC6A3SLC6A4CYP2D6KIF11 | |
| SCHEMBL4469070 | 0.77 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4458632 | 0.76 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4465320 | 0.76 | SLC6A2 (0.64) | SLC6A2SLC6A3SLC6A4CYP2D6 | |
| SCHEMBL4464065 | 0.76 | SLC6A4 (0.65) | SLC6A2SLC6A3SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246806-B1 | ARLY- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY INC (US) | 2008-02-27 | — | — | EP | claimed |
| EP-1819337-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR Technology, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006058016-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-06-01 | — | — | WO | claimed |
| US-20060111395-A1 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | claimed |
| US-20060111394-A1 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | claimed |
| US-6579885-B2 | For therapy of attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, Parkinsonism | ALBANY MOLECULAR RESEARCH, INC. | 2003-06-17 | — | — | US | claimed |
| EP-1246806-A1 | ARLY- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020143014-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | BARCLAYS BANK PLC, AS THE COLLATERAL AGENT | 2002-10-03 | — | — | US | claimed |
| WO-2001032625-A1 | ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-05-10 | — | — | WO | claimed |
| US-7612090-B2 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1246806-B1 | ARLY- AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-7265116-B2 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | ARM TECHNOLOGY, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060111395-A1 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060111394-A1 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050020597-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | BARCLAYS BANK PLC, AS THE COLLATERAL AGENT | 2005-01-27 | — | — | US | disclosed |
| US-20030203920-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2003-10-30 | — | — | US | disclosed |
| US-6579885-B2 | For therapy of attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, Parkinsonism | ALBANY MOLECULAR RESEARCH, INC. | 2003-06-17 | — | — | US | disclosed |
| US-20020143014-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | BARCLAYS BANK PLC, AS THE COLLATERAL AGENT | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111394-A1 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | SLC6A2, ADRA1B, TPH1 | SLC6A2 1/4885SLC6A3 8/4885SLC6A4 19/4885 |
| US-20060111395-A1 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | SLC6A2, TPH1, ADRA1B | SLC6A2 1/4885SLC6A3 6/4885SLC6A4 17/4885 |
| US-20030203920-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | TPH1, TPH2, HTR1A | SLC6A2 12/4885SLC6A3 22/4885SLC6A4 27/4885 |
| US-20020143014-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | TPH1, TPH2, HTR1A | SLC6A2 12/4885SLC6A3 22/4885SLC6A4 27/4885 |
| US-20050020597-A1 | Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof | TPH1, HTR2C, HTR1A | SLC6A2 35/4885SLC6A3 19/4885SLC6A4 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.